NASDAQ:FEED Nanovibronix (FEED) Stock Price, News & Analysis $0.82 -0.01 (-1.59%) As of 01:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Nanovibronix Stock (NASDAQ:FEED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nanovibronix alerts:Sign Up Key Stats Today's Range$0.81▼$0.8750-Day Range$0.75▼$1.9652-Week Range$0.72▼$17.40Volume257,129 shsAverage Volume7.32 million shsMarket Capitalization$4.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings. The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves. As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.AI Generated. May Contain Errors. Read More Nanovibronix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreFEED MarketRank™: Nanovibronix scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingNanovibronix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNanovibronix has only been the subject of 1 research reports in the past 90 days.Read more about Nanovibronix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nanovibronix is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nanovibronix is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanovibronix has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.10% of the float of Nanovibronix has been sold short.Short Interest Ratio / Days to CoverNanovibronix has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanovibronix has recently decreased by 61.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanovibronix does not currently pay a dividend.Dividend GrowthNanovibronix does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.96 News SentimentNanovibronix has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nanovibronix this week, compared to 2 articles on an average week.Search Interest4 people have searched for FEED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nanovibronix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nanovibronix insiders have not sold or bought any company stock.Percentage Held by Insiders1.40% of the stock of Nanovibronix is held by insiders.Percentage Held by Institutions16.39% of the stock of Nanovibronix is held by institutions.Read more about Nanovibronix's insider trading history. Receive FEED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanovibronix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FEED Stock News HeadlinesENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube NavigationJune 9, 2026 | globenewswire.comENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health NetworkJune 5, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.June 15 at 1:00 AM | Banyan Hill Publishing (Ad)ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital SystemJune 3, 2026 | globenewswire.comENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026May 19, 2026 | globenewswire.comENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of CareMay 12, 2026 | globenewswire.comENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery TechnologyMay 8, 2026 | globenewswire.comENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 HospitalsMay 7, 2026 | globenewswire.comSee More Headlines FEED Stock Analysis - Frequently Asked Questions How have FEED shares performed this year? Nanovibronix's stock was trading at $2.30 on January 1st, 2026. Since then, FEED shares have decreased by 64.1% and is now trading at $0.8250. How were Nanovibronix's earnings last quarter? Nanovibronix, Inc. (NASDAQ:FEED) issued its earnings results on Monday, May, 18th. The company reported ($6.88) earnings per share (EPS) for the quarter. The firm had revenue of $0.65 million for the quarter. Nanovibronix had a negative trailing twelve-month return on equity of 54.25% and a negative net margin of 923.20%. How do I buy shares of Nanovibronix? Shares of FEED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/18/2026Today6/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 FEED's financial health is in the Yellow zone, according to TradeSmith. FEED has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Surgical, Medical, And Dental Instruments And Supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:FEED CIK1326706 WebN/A Phone(914) 233-3004Fax914-376-6111Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($8.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.18 million Net Margins-923.20% Pretax Margin-936.45% Return on Equity-54.25% Return on Assets-43.10% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.57 Sales & Book Value Annual Sales$2.18 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$30.44 per share Price / Book0.03Miscellaneous Outstanding Shares6,092,000Free Float5,775,000Market Cap$4.97 million OptionableN/A Beta1.51 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:FEED) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanovibronix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanovibronix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.